Niranjan Sardesai | President & Chief Executive Officer, Founder
Geneos Therapeutics
Dr. Sardesai founded Geneos after building Inovio Pharmaceuticals into a Phase III cancer and infectious disease immunotherapy company serving as its Chief Operating Officer. He held positions of increasing responsibility after joining the company in 2006 where he helped formulate the company’s product development and growth strategies and reorganized the company into a DNA vaccine and immunotherapies company. For Inovio, Dr. Sardesai drove multiple M&A and licensing transactions to consolidate key technologies, establish the corporate footprint, and develop its immunotherapies platform and product pipeline. He led the strategic out-licensing of Inovio’s pipeline products to secure major licensing deals totaling over $1 Bn with pharma partners.
Appearances:
Main Congress Day 2 - 23rd April @ 17:40
DNA-based personalized therapeutic cancer vaccines in advanced HCC and GBM
Main Congress Day 3 - 24th April @ 11:30
Panel: Cancer vaccines vs Adoptive T-cell Therapies – what can we learn?
- li>
- Adoptive T-cell therapies have proved potent for leukemia but not solid tumors - what is missing to infiltrate tumors, what do they not have that cancer vaccines do?
- Cancer vaccines targeting multiple antigens simultaneously drive t-cell responses more broadly, less likely to drive escape than Adoptive T-cell therapy.
- Examples of combinations, can cancer vaccines provide “life support” to failing adoptive t-cell therapies by prolonging T-cell persistence?
- Where should each type of therapy by used
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events